InsidersTradesSigma
OncoCyte Corp Stock: price and management transactions · United States · SEC (Form 4)
Follow the OncoCyte Corp stock price and the full directors' dealings record of the company, a listed equity based in United States. Shares are listed on US US, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, OncoCyte Corp has recorded 70 reports. The latest transaction was disclosed on 11 February 2025 (Acquisition). Among the most active insiders: Arno Andrew. The full history is free.
70
Insider Decl.
0
Thresholds
€34m
32 ops.
Buy Volume
€10,958
3 ops.
Sell Volume
49Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 11 February 2025
Declarations70 total
97,561 shares@ US$2.0559.0% of flowCommon Stock, no par valueSEC:0001493152-25-005978:0
Ideal exit: 4 Nov 2025 (T+270)
1,077,600 shares@ US$2.0591.2% of flowCommon Stock, no par valueSEC:0001493152-25-005942:0
Ideal exit: 4 Nov 2025 (T+270)
660,207 shares@ US$2.054.4% of flowCommon Stock, no par valueSEC:0000919574-25-000922:0
Ideal exit: 3 Nov 2025 (T+270)
890 shares@ US$2.010.1% of flowCommon Stock, no par valueSEC:0001493152-25-004871:0
Ideal exit: 28 Oct 2025 (T+270)
3,880 shares@ US$2.010.3% of flowCommon Stock, no par valueSEC:0001493152-25-004470:0
Ideal exit: 26 Oct 2025 (T+270)
5,669 shares@ US$2.080.5% of flowCommon Stock, no par valueSEC:0001493152-25-002410:0
Ideal exit: 10 Oct 2025 (T+270)
90,219 shares@ US$2.137.9% of flowCommon Stock, no par valueSEC:0001493152-24-052334:0
Ideal exit: 22 Sept 2025 (T+270)
12,500 shares@ US$2.10810.0% of flowCommon Stock, no par valueSEC:0001493152-24-052168:0
Ideal exit: 22 Sept 2025 (T+270)
20,000 shares@ US$2.2913.3% of flowCommon Stock, no par valueSEC:0001493152-24-049195:0
Ideal exit: 1 Sept 2025 (T+270)
33,670 shares@ US$2.9727.7% of flowCommon Stock, no par valueSEC:0001493152-24-039603:0
Ideal exit: 29 Jun 2025 (T+270)
1,315,339 shares@ US$2.94812.0% of flowCommon Stock, no par valueSEC:0000919574-24-005764:0
Ideal exit: 29 Jun 2025 (T+270)
3,390 shares@ US$2.95100.0% of flowCommon Stock, no par valueSEC:0001493152-24-014512:0
Ideal exit: 6 Jan 2025 (T+270)
33,898 shares@ US$2.9536.7% of flowCommon Stock, no par valueSEC:0001493152-24-014509:0
Ideal exit: 6 Jan 2025 (T+270)
2,420,000 shares@ US$2.916422.5% of flowCommon Stock, no par valueSEC:0000919574-24-002558:0
Ideal exit: 6 Jan 2025 (T+270)
3,085,047 shares0Common Stock, no par valueSEC:0000899243-23-016837:0
20,000 shares0Common Stock, no par valueSEC:0001493152-23-022667:0
20,000 shares0Common Stock, no par valueSEC:0001493152-23-022669:0
30,000 shares0Common Stock, no par valueSEC:0001493152-23-022668:0
25,000 shares0Common Stock, no par valueSEC:0001493152-23-022666:0
30,000 shares@ US$0.214947.0% of flowCommon Stock, no par valueSEC:0001493152-23-021531:0
Ideal exit: 10 Mar 2024 (T+270)
3,890,111 sharesCommon StockSEC:0001209191-23-024720:0
663,000 shares@ US$0.30174.2% of flowCommon StockSEC:0001209191-23-023828:0
Ideal exit: 31 Dec 2023 (T+270)
705,000 shares@ US$0.354490.8% of flowCommon Stock, no par valueSEC:0001493152-23-011106:0
141,084 shares@ US$0.354418.0% of flowCommon Stock, no par valueSEC:0001493152-23-011104:0
26,827,638 shares@ US$0.301725.3% of flowCommon Stock, no par valueSEC:0000919574-23-002420:0
Ideal exit: 29 Dec 2023 (T+270)
25 of 70 declarations
About OncoCyte Corp
OncoCyte Corp (ticker: OCX) is a U.S.-based precision diagnostics company listed on the NASDAQ in the United States. Headquartered in Irvine, California, the company develops and commercializes molecular diagnostic tests designed to provide physicians with actionable information at critical decision points across the patient-care pathway, with an emphasis on oncology and transplantation. Its business model is more aligned with specialized diagnostics than with traditional pharmaceuticals, focusing on clinical decision support rather than drug development. From a historical perspective, OncoCyte has been built through a combination of internal development and targeted acquisitions of diagnostic technologies. Company disclosures indicate that the acquisition of Chronix Biomedical expanded its scientific capabilities in circulating biomarkers and cell-free DNA. The company operates under the Oncocyte brand and maintains a meaningful operational footprint in Irvine, along with a CLIA-certified laboratory in Nashville, Tennessee. That regulated laboratory infrastructure is strategically important in the U.S. diagnostics market, where analytical validation, clinical utility, and reimbursement are key determinants of commercial adoption. OncoCyte’s main business lines are now centered on transplant diagnostics and, more broadly, on tests that help classify or monitor patients. The GraftAssure franchise has become the core of the company’s growth narrative: these assays measure donor-derived cell-free DNA (dd-cfDNA) to monitor organ health after transplantation, particularly in kidney transplant settings. The company also retains legacy oncology-related assets, including gene-expression-based tests and tools intended to support treatment decisions. In commercial terms, OncoCyte is targeting specialized, high-value niches where more accurate testing may improve treatment decisions and potentially lower overall care costs. Competitively, OncoCyte operates in a demanding market shaped by larger, better-capitalized molecular diagnostics companies and reference laboratories with broader distribution reach. Its differentiation depends on clinical validation, intellectual property, product specialization, and strategic partnerships. Recent company updates point to a business that is still scaling commercially: in 2025 and 2026, management emphasized progress in broader adoption of GraftAssure and continued execution around transplant-diagnostics expansion. For investors, OncoCyte is therefore a high-risk, innovation-driven diagnostics story, with value creation tied to regulatory milestones, reimbursement progress, and the pace of clinical adoption.
